Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)12.91bn
- Net income in MXN885.84m
- Incorporated1996
- Employees1.29k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeMEXICO, D.F. 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttp://www.genommalab.com/mx/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotoscana Investments SA | 3.05bn | 6.58m | 4.25bn | 677.00 | 1,007.06 | 1.43 | 25.35 | 1.39 | 0.0099 | 0.0099 | 7.00 | 6.98 | 0.5944 | 2.01 | 2.86 | 1,097,632.00 | 0.1281 | 2.29 | 0.1796 | 3.06 | 46.49 | 50.40 | 0.2155 | 3.14 | 0.8399 | 3.24 | 0.2044 | 0.00 | -9.48 | 12.83 | -97.48 | -38.45 | -- | -- |
| Ouro Fino Saude Animal Participacoes SA | 2.63bn | 203.50m | 5.32bn | 1.01k | 26.14 | 2.64 | 17.27 | 2.02 | 0.9183 | 0.9183 | 11.87 | 9.10 | 0.7268 | 1.85 | 5.02 | -- | 5.62 | 5.60 | 7.54 | 7.38 | 49.17 | 52.75 | 7.73 | 8.02 | 1.08 | 5.58 | 0.412 | 25.15 | 5.15 | -- | -32.78 | -- | -- | -- |
| Genomma Lab Internacional SAB de CV | 12.91bn | 885.84m | 20.32bn | 1.29k | 22.80 | 2.26 | 19.71 | 1.57 | 0.8504 | 0.8504 | 12.52 | 8.58 | 0.6489 | 2.43 | 3.54 | 11,354,070.00 | 4.45 | 0.6212 | 6.59 | 0.8722 | 63.03 | 66.05 | 6.86 | 0.9447 | 1.39 | 4.33 | 0.4178 | 0.00 | 7.79 | 1.95 | -31.10 | -11.79 | -0.6157 | -- |
| Hypera SA | 15.31bn | 4.54bn | 73.76bn | 7.52k | 16.07 | 2.04 | 14.66 | 4.82 | 1.77 | 1.73 | 5.95 | 13.92 | 0.3322 | 1.89 | 3.44 | 495,835.40 | 9.86 | 7.30 | 11.12 | 8.82 | 65.56 | 71.42 | 29.69 | 26.51 | 2.56 | -- | 0.1917 | 48.64 | -11.53 | 3.54 | 4.72 | 28.61 | 12.14 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Massachusetts Financial Services Co.as of 31 Mar 2020 | 56.77m | 5.42% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2020 | 50.42m | 4.81% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2020 | 35.95m | 3.43% |
| The Vanguard Group, Inc.as of 30 Apr 2020 | 25.48m | 2.43% |
| Invesco Advisers, Inc.as of 31 Dec 2019 | 22.25m | 2.12% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 07 May 2020 | 22.20m | 2.12% |
| Dimensional Fund Advisors LPas of 07 May 2020 | 18.18m | 1.74% |
| BlackRock Fund Advisorsas of 07 May 2020 | 12.45m | 1.19% |
| Norges Bank Investment Managementas of 31 Dec 2019 | 12.39m | 1.18% |
| AllianceBernstein LPas of 31 Mar 2020 | 8.77m | 0.84% |
